AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14656717 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological dose of insulin (20 mU.kg(‐1).min(‐1) euglycemic hyperinsulinemic clamp x 2 h, n = 9)
Number of subjects: 24
Study 11985906 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular function (measured by fractional area change [FAC])
Number of subjects: 416
Study 11985906 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular function (measured by FAC)
Number of subjects: 416
Study 9661645 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH plus GHRP-6 (90 micrograms each, administered intravenously as a bolus)
Number of subjects: 26
Study 9375232 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified process dissociation procedure using multidimensional signal detection theory (SDT)
Number of subjects: 0
Study 9375232 — intervention group
Group type: COMPARATOR
Intervention: Hybrid procedure preferred by Jacoby et al. (1993)
Number of subjects: 0
Study 9375232 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified process dissociation procedure using SDT
Number of subjects: 0
Study 9375232 — intervention group
Group type: EXPERIMENTAL
Intervention: SDT analysis
Number of subjects: 0
Study 2566251 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 60
Study 2566251 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 60
Study 56591 — intervention group
Group type: COMPARATOR
Intervention: Transfusion to a Hb of 10‐12 g/dl (group A)
Number of subjects: 30
Study 56591 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypertransfusion to a Hb of 14‐16 g/dl (group B)
Number of subjects: 30
Study 6156614 — intervention group
Group type: EXPERIMENTAL
Intervention: antithymocyte globulin
Number of subjects: 41
Study 6156614 — intervention group
Group type: COMPARATOR
Intervention: human leukocyte interferon
Number of subjects: 41
Study 31758247 — intervention group
Group type: EXPERIMENTAL
Intervention: GI‐pill gastrointestinal electronic capsule
Number of subjects: 162
Study 31758247 — intervention group
Group type: COMPARATOR
Intervention: X‐ray granule capsule
Number of subjects: 162
Study 30261178 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless, hands-free audio system
Number of subjects: 960
Study 30261178 — intervention group
Group type: COMPARATOR
Intervention: Standard Da Vinci Si speaker system
Number of subjects: 960
Study 28202108 — intervention group
Group type: EXPERIMENTAL
Intervention: PS + budesonide
Number of subjects: 30
Study 28202108 — intervention group
Group type: COMPARATOR
Intervention: PS alone
Number of subjects: 30
Study 26024701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 99
Study 26024701 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 99
Study 26024701 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Pregabalin vs Propranolol
Number of subjects: 99
Study 22939518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lisinopril and irbesartan (n = 70)
Number of subjects: 133
Study 22939518 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (n = 35)
Number of subjects: 133
Study 22939518 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (n = 28)
Number of subjects: 133
Study 22939518 — intervention group
Group type: COMPARATOR
Intervention: Combination of lisinopril and irbesartan
Number of subjects: 133
Study 22939518 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 133
Study 20652533 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (Group I)
Number of subjects: 45
Study 20652533 — intervention group
Group type: COMPARATOR
Intervention: Computer-assisted surgery (Group II)
Number of subjects: 45
Study 20652533 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive technique combined with computer-assisted surgery (Group III)
Number of subjects: 45
Study 19969216 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin 0.5% drops
Number of subjects: 464
Study 19969216 — intervention group
Group type: COMPARATOR
Intervention: Normal saline drops (control group)
Number of subjects: 464
Study 17197857 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (3.3 mg ED95) combined with 1.5 microg sufentanil
Number of subjects: 450
Study 17197857 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (4.8 mg ED95) combined with 1.5 microg sufentanil
Number of subjects: 450
Study 17197857 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (5.0 mg ED95) combined with 1.5 microg sufentanil
Number of subjects: 450
Study 15593224 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment response
Number of subjects: 66
Study 15593224 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter disease duration (<=12 months)
Number of subjects: 66
Study 12173010 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT MBF corrected by RPP in smokers (0.65 ± 0.12 ml g(‐1) min(‐1))
Number of subjects: 30
Study 12173010 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT induced increase in rate-pressure product (RPP) in smokers (10,430 ± 1,820 beats min(‐1) mmHg(‐1))
Number of subjects: 30
Study 12173010 — intervention group
Group type: COMPARATOR
Intervention: Rest MBF in smokers (0.86 ± 0.11 ml g(‐1) min(‐1))
Number of subjects: 30
Study 12173010 — intervention group
Group type: COMPARATOR
Intervention: Hyperaemic MBF during ATP infusion in smokers (3.20 ± 1.12 ml g(‐1) min(‐1))
Number of subjects: 30
Study 12173010 — intervention group
Group type: COMPARATOR
Intervention: Coronary flow reserve in smokers (3.78 ± 1.83)
Number of subjects: 30
Study 12173010 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT MBF to resting MBF ratio
Number of subjects: 30
Study 10213108 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium:YAG laser vaporization
Number of subjects: 36
Study 10213108 — intervention group
Group type: COMPARATOR
Intervention: Transurethral electroresection (TURP)
Number of subjects: 36
Study 8553632 — intervention group
Group type: EXPERIMENTAL
Intervention: Zontac (histamine H2-receptor blocking agent) administered intravenously 50 mg thrice a day for 3 days, then orally 150 mg twice a day for 3 weeks
Number of subjects: 33
Study 8553632 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy (control group)
Number of subjects: 33
Study 2146911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 125
Study 2146911 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 125
Study 402459 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasojejunal feeding (NJ)
Number of subjects: 18
Study 402459 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric tube feeding (NG)
Number of subjects: 18
Study 30925074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dysarthria therapy (three 40-minute sessions per week for six weeks)
Number of subjects: 22
Study 30925074 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 22
Study 31165715 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month online group-based nurse-led intervention
Number of subjects: 133
Study 31165715 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 133
Study 29061081 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (100 mg)
Number of subjects: 36
Study 26013051 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT) at 85‐95% of HRmax, performed twice a week for 10 weeks on spinning bikes.
Number of subjects: 18
Study 26013051 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Number of subjects: 18
Study 23163880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 12.5 mg
Number of subjects: 0
Study 23163880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg
Number of subjects: 0
Study 23163880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 150 mg
Number of subjects: 0
Study 23163880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 300 mg
Number of subjects: 0
Study 23163880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23163880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin (all doses)
Number of subjects: 0
Study 21752511 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 40
Study 21752511 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 0.125 mg/mL epinephrine
Number of subjects: 40
Study 21752511 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 0.006 mg/mL epinephrine
Number of subjects: 40
Study 21752511 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 0.012 mg/mL epinephrine
Number of subjects: 40
Study 19001558 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoes on
Number of subjects: 100
Study 19001558 — intervention group
Group type: COMPARATOR
Intervention: Shoes off
Number of subjects: 100
Study 16764623 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (n = 52)
Number of subjects: 106
Study 16764623 — intervention group
Group type: COMPARATOR
Intervention: Primary surgery (n = 54)
Number of subjects: 106
Study 16764623 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable disease (n unspecified)
Number of subjects: 106
Study 16764623 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent disease (n unspecified)
Number of subjects: 106
Study 16764623 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial response (n = 6)
Number of subjects: 106
Study 16764623 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable disease (n = 4)
Number of subjects: 106
Study 16764623 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial response and complete response (n = 38)
Number of subjects: 106
Study 15385832 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus starting dose of 0.75 mg bid (n = 112)
Number of subjects: 237
Study 15385832 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus starting dose of 1.5 mg bid (n = 125)
Number of subjects: 237
Study 15385832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine dosing
Number of subjects: 237
Study 15385832 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus C0 between 3 and 8 ng/mL
Number of subjects: 237
Study 12386499 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 12386499 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin
Number of subjects: 0
Study 12386499 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolytics
Number of subjects: 0
Study 12386499 — intervention group
Group type: COMPARATOR
Intervention: Magnesium
Number of subjects: 0
Study 10343660 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention details not available
Number of subjects: 0
Study 10343660 — intervention group
Group type: COMPARATOR
Intervention: Control details not available
Number of subjects: 0
Study 7658304 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% itraconazole cream
Number of subjects: 12
Study 7658304 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50% itraconazole cream
Number of subjects: 12
Study 7658304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2794192 — intervention group
Group type: EXPERIMENTAL
Intervention: Model videotape of the principal investigator presenting a case to a parent
Number of subjects: 72
Study 2794192 — intervention group
Group type: COMPARATOR
Intervention: Students evaluating their own videotaped presentation
Number of subjects: 72
Study 326330 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplopen
Number of subjects: 368
Study 326330 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin
Number of subjects: 368
Study 326330 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 368
Study 31412753 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 1762
Study 28657791 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-load group (HLG)
Number of subjects: 27
Study 28657791 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-load group (LLG)
Number of subjects: 27
Study 28657791 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 27
Study 26502987 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (50-min presentation)
Number of subjects: 2173
Study 26502987 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2173
Study 24370959 — intervention group
Group type: EXPERIMENTAL
Intervention: Video exoscopy
Number of subjects: 300
Study 24370959 — intervention group
Group type: COMPARATOR
Intervention: Colposcopy
Number of subjects: 300
Study 22352799 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope
Number of subjects: 24
Study 22352799 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 24
Study 20130095 — intervention group
Group type: COMPARATOR
Intervention: Control (0% DHA)
Number of subjects: 343
Study 20130095 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.32% DHA
Number of subjects: 343
Study 20130095 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.64% DHA
Number of subjects: 343
Study 20130095 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.96% DHA
Number of subjects: 343
Study 18090696 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (120.9 +/- 50.0 mg)
Number of subjects: 50
Study 18090696 — intervention group
Group type: COMPARATOR
Intervention: Methohexital (83 +/- 26.3 mg)
Number of subjects: 50
Study 16275379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with standardized hazelnut extract
Number of subjects: 23
Study 16275379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 12175374 — intervention group
Group type: EXPERIMENTAL
Intervention: IMZ implants
Number of subjects: 40
Study 12175374 — intervention group
Group type: COMPARATOR
Intervention: ITI implants
Number of subjects: 40
Study 12175374 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 10528614 — intervention group
Group type: EXPERIMENTAL
Intervention: pi-plate
Number of subjects: 0
Study 10528614 — intervention group
Group type: COMPARATOR
Intervention: two 1/4 tube plates
Number of subjects: 0
Study 7669314 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% sevoflurane
Number of subjects: 68
Study 7669314 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5% sevoflurane
Number of subjects: 68
Study 7669314 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% sevoflurane
Number of subjects: 68
Study 7669314 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% sevoflurane
Number of subjects: 68
Study 7669314 — intervention group
Group type: EXPERIMENTAL
Intervention: All concentrations
Number of subjects: 68
Study 2200879 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular cantilevered fixed partial dentures (FPDs)
Number of subjects: 53
Study 2200879 — intervention group
Group type: COMPARATOR
Intervention: Distal-extension removable partial dentures (RPDs)
Number of subjects: 53
Study 7295615 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (1%) eye drops
Number of subjects: 0
Study 7295615 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (0.25%) eye drops
Number of subjects: 0
Study 7295615 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (0.5%) eye drops
Number of subjects: 0
Study 7295615 — intervention group
Group type: COMPARATOR
Intervention: Pindolol (1%) and Timolol (0.25% and 0.5%)
Number of subjects: 0
Study 30640285 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic strength of the injured limb at RTS
Number of subjects: 41
Study 30640285 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic strength at RTS
Number of subjects: 41
Study 30640285 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of isokinetic strength at RTS with preinjury strength
Number of subjects: 41
Study 28126625 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS over left temporal lobe (T3)
Number of subjects: 34
Study 28126625 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 34
Study 26782861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (algorithm-based care for depression provided by a depression care manager for 2 years)
Number of subjects: 1226
Study 26782861 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1226
Study 26782861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (algorithm-based care for depression)
Number of subjects: 1226
Study 25161072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat(®)
Number of subjects: 409
Study 22383665 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol pMDI 320/9 μg or 160/9 μg
Number of subjects: 2866
Study 22383665 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide pMDI 320 μg + formoterol dry powder inhaler 9 μg
Number of subjects: 2866
Study 22383665 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide pMDI 320 μg
Number of subjects: 2866
Study 22383665 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol dry powder inhaler 9 μg
Number of subjects: 2866
Study 22383665 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2866
Study 18838411 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior segment OCT nuclear density measurement
Number of subjects: 55
Study 18838411 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior segment OCT measurement
Number of subjects: 55
Study 17218187 — intervention group
Group type: EXPERIMENTAL
Intervention: Information plus a brief motivational intervention (n=416)
Number of subjects: 830
Study 17218187 — intervention group
Group type: COMPARATOR
Intervention: Information only (n=414)
Number of subjects: 830
Study 15833834 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole therapy for 1 month
Number of subjects: 0
Study 15833834 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole therapy for 3 months
Number of subjects: 0
Study 15833834 — intervention group
Group type: COMPARATOR
Intervention: Pretreatment sEGFR concentrations
Number of subjects: 0
Study 12228882 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical method for exploring heterogeneity in meta-analyses
Number of subjects: 10850
Study 9884249 — intervention group
Group type: EXPERIMENTAL
Intervention: C2 (700-1000 ng/ml)
Number of subjects: 35
Study 9884249 — intervention group
Group type: COMPARATOR
Intervention: C0 (100-200 ng/ml)
Number of subjects: 35
Study 9884249 — intervention group
Group type: EXPERIMENTAL
Intervention: C2 (300-600 ng/ml)
Number of subjects: 35
Study 8571773 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular suture using absorbable material (Dexon)
Number of subjects: 80
Study 8571773 — intervention group
Group type: COMPARATOR
Intervention: Continuous transdermal blanket suture using nonabsorbable material (silk)
Number of subjects: 80
Study 1535202 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia (2.5 mg/kg)
Number of subjects: 60
Study 1535202 — intervention group
Group type: COMPARATOR
Intervention: Thiamylal-enflurane anesthesia (4 mg/kg)
Number of subjects: 60
Study 6498579 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 0.01 mg X kg‐1 IV, administered two minutes prior to induction
Number of subjects: 40
Study 6498579 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 0.01 mg X kg‐1 IV, administered five minutes prior to induction
Number of subjects: 40
Study 6498579 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 0.01 mg X kg‐1 IV, administered eight minutes prior to induction
Number of subjects: 40
Study 6498579 — intervention group
Group type: COMPARATOR
Intervention: Saline pretreatment, administered five minutes prior to induction
Number of subjects: 40
Study 31357408 — intervention group
Group type: EXPERIMENTAL
Intervention: Education-based intervention
Number of subjects: 0
Study 31357408 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30012178 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure™
Number of subjects: 69
Study 30012178 — intervention group
Group type: EXPERIMENTAL
Intervention: HARMONIC ACE®+7
Number of subjects: 69
Study 30012178 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical techniques (titanium clips and conventional knot-tying ligations)
Number of subjects: 69
Study 26861957 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo-activated platelet-rich plasma (PA-PRP)
Number of subjects: 37
Study 26861957 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 37
Study 25936814 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (total dose of 6.0 Gy applied in 6 fractions of 1.0 Gy three times a week)
Number of subjects: 128
Study 25936814 — intervention group
Group type: COMPARATOR
Intervention: Local corticosteroid injections (1 ml injection of 40 mg methylprednisolone and 0.5 ml 1% lidocaine under the guidance of palpation)
Number of subjects: 128
Study 23566060 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed supplementation (30 g/day) for 30 days
Number of subjects: 147
Study 20623950 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed scoring system of diagnostics of GBC
Number of subjects: 124
Study 20623950 — intervention group
Group type: EXPERIMENTAL
Intervention: Diminished scoring system of diagnostics of GBC
Number of subjects: 124
Study 18156147 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive school‐randomized fruit and vegetable intervention program
Number of subjects: 0
Study 18156147 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16491348 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrografin (350 ml) of three different concentrations
Number of subjects: 4
Study 16491348 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol, iohexol, or iodixanol with equivalent osmolarities
Number of subjects: 4
Study 16491348 — intervention group
Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 4
Study 14684757 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 fl. oz. orange juice
Number of subjects: 11
Study 14684757 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 fl. oz. orange juice
Number of subjects: 11